The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.


Updates from The Motley Fool

Latest updates on Affymax, Inc. from Fool.com.  The Fool has written over 100 articles on Affymax, Inc..
The Nasdaq's 5 Most Hated Stocks

The Nasdaq hasn't had a down month this year, but that's not stopping skeptics from piling onto t...

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

4 Stocks Making Moves

Monday's four biggest movers of the day, on Investor Beat.

What's Next for Affymax?

Affymax prepares to take on Amgen's 20-year hold on the dialysis market.

The Best of 2012: Affymax

Affymax's drug treating anemia in dialysis patients was FDA approved this year, and is now a majo...



Stock Performance

View Interactive AFFY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Affymax, Inc..
Current Price: $0.06
Prev Close: $0.06
Open: $0.06
Bid: $0.00
Ask: $0.00
Day's Range: $0.06 - $0.06
52wk Range: $0.05 - $0.10
Volume: 117,275
Avg Vol 24,796
Market Cap: $2M
P/E (ttm): 0.80
EPS (ttm): $0.00
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Affymax, Inc..
CAPS Rating 2 out of 5
 
102 Outperform
36 Underperform
CAPS All Stars
 
8 Outperform
9 Underperform

How do you think Affymax, Inc. will perform against the market?



You pick for Affymax, Inc. is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Affymax, Inc..

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

  • Exchange: NASDAQOTH
  • Sector: Healthcare
  • Industry: Drug Makers